In a significant leadership transition for the molecular diagnostics sector, Natera, the Austin-based leader in cell-free DNA (cfDNA) testing, has announced that Solomon Moshkevich, a 15-year veteran of the company, has been appointed as its new Chief Executive Officer. The appointment, effective immediately, marks the end of a long and successful tenure for outgoing CEO Steve Chapman, who has steered the company through a period of immense growth and market expansion.
While the board of directors and the incoming CEO are emphasizing continuity and long-term vision, the news triggered a sharp reaction on Wall Street. Despite the company reporting robust third-quarter financial results, Natera shares tumbled nearly 14% on the news, highlighting the market’s sensitivity to sudden executive changes within high-growth biotech firms.
The Core Transition: A Strategic Handover
Solomon Moshkevich’s ascension to the CEO role is framed by the company as a natural evolution. Having served as the President of Clinical Diagnostics, Moshkevich is widely credited with the operational backbone of Natera’s current portfolio. His deep institutional knowledge, spanning over a decade and a half, is intended to reassure stakeholders that the firm’s strategic trajectory—focused on oncology, women’s health, and organ health—remains unchanged.
Moshkevich’s career at Natera has been characterized by his "hands-on" approach to product development. He has been instrumental in the clinical validation and commercial rollout of Natera’s signature tests, including:
- Panorama: A non-invasive prenatal screening test that has become a standard of care.
- Prospera: A revolutionary tool for assessing the risk of organ rejection in transplant recipients.
- Signatera: A molecular residual disease (MRD) test that has fundamentally changed the landscape of cancer recurrence detection.
Beyond his role in product development, Moshkevich has led diverse teams across global marketing, regulatory affairs, quality assurance, and scientific affairs. As the company’s first general manager of oncology, he was the primary architect of Natera’s aggressive and successful expansion into the cancer diagnostics space, a sector that now serves as a major growth engine for the firm.
Chronology of the Transition
The departure of Steve Chapman concludes a seven-year chapter defined by scaling Natera from a niche player to a powerhouse in the molecular diagnostics industry.
- 2017–2024: Steve Chapman oversees a period of rapid revenue expansion and the successful commercialization of the Signatera platform, securing Natera’s position as a market leader in MRD testing.
- November 2024: Natera releases its Q3 financial results, showcasing a 34.1% year-over-year revenue increase.
- November 2024 (Simultaneous): The board announces the immediate transition of leadership. Steve Chapman steps down as CEO but joins the board of directors as an adviser, while also transitioning into a long-term consulting role to ensure a smooth handoff.
- Immediate Future: Moshkevich assumes full control of the company’s strategic vision, with a mandate to maintain the momentum established under his predecessor.
Supporting Data: A Financial Snapshot
The leadership news arrived alongside a strong quarterly report that underscored the operational health of the company. Natera reported revenue of $794 million for the third quarter of 2024, a 34.1% increase compared to the same period in the previous year.
Despite these strong fundamentals, the market reaction was swift and negative. Shares fell nearly 14% to $312.98 by midday Friday, as investors grappled with the unexpected nature of the announcement. Analysts have noted that while the financial metrics are stellar, the "unpredictability" of the move created an immediate premium of uncertainty that traders were quick to act upon.
The company’s growth is fueled by a high-volume adoption of its cfDNA testing across both the oncology and transplant markets. By providing doctors with actionable, "precision-medicine" insights, Natera has successfully built a moat around its technology, making its tests difficult to replace in standard clinical workflows.
Official Responses and Investor Sentiment
The transition has been met with a mix of praise for the departing CEO and cautious optimism for his successor. Steve Chapman, in an official statement, expressed his full confidence in Moshkevich.
"Solomon has been deeply involved with every major decision the company has made, and has my full support," Chapman stated. By positioning himself as a long-term consultant and board adviser, Chapman is signaling to institutional investors that the "DNA" of the company’s strategy remains intact.
Industry analysts have provided a balanced view of the shift. TD Cowen analyst Dan Brennan noted that while Chapman’s performance was "extremely strong" and consistent, the immediacy of the departure created "initial angst." Similarly, BNP Paribas Equity Research analyst Navann Ty highlighted the benefit of promoting from within, noting that Moshkevich’s tenure should "provide some continuity" during a time of market flux.
Canaccord Genuity analyst Kyle Mikson echoed these sentiments, stating that Moshkevich’s extensive experience across every facet of the business—from clinical trials to regulatory and business development—provides him with the necessary toolkit to navigate the complexities of the current diagnostic market.
Implications for the Future: The "Next Frontier"
As Moshkevich steps into the role, his vision for Natera appears to be rooted in deepening the company’s clinical utility. "In the years ahead, we intend to generate more diagnostic insights from every clinical sample, bring novel technologies to new patient populations, and integrate more seamlessly at the point of care," Moshkevich said in his first address as CEO.
The implications of this leadership change are threefold:
1. Continued Focus on Oncology
Under Moshkevich’s leadership, Natera is expected to double down on its oncology portfolio. With the Signatera test leading the market in detecting cancer recurrence, the company is likely to focus on expanding insurance coverage and clinical adoption rates, effectively pushing MRD testing from a "specialized" tool to a routine part of oncology care.
2. Operational Stability vs. Growth
Investors will be watching closely to see if Moshkevich can maintain the high-growth pace set by Chapman while improving margins. The challenge for the new CEO will be to manage the high operational costs associated with clinical trials and large-scale diagnostic testing while satisfying the market’s demand for sustained profitability.
3. Regulatory and Competitive Moats
Natera operates in a highly regulated and fiercely competitive environment. Moshkevich’s background in regulatory affairs is a major asset here. As competitors attempt to enter the cfDNA space, Moshkevich’s intimate understanding of the FDA landscape and clinical trial operations will be essential in maintaining Natera’s technological lead.
Conclusion
The appointment of Solomon Moshkevich as CEO of Natera represents a pivotal moment for the company. By choosing an executive who helped build the company’s most successful products from the ground up, the board is betting on continuity over radical change. While the market reaction has been volatile, the underlying financial health and the long-term potential of Natera’s testing portfolio remain robust.
For Moshkevich, the task is clear: he must bridge the gap between Natera’s past success as a growth-stage disruptor and its future as a mature, essential component of the global precision medicine infrastructure. If his history at the company is any indicator, he is well-prepared to navigate the challenges ahead, provided he can steady the nerves of an investor base that has grown accustomed to the predictability of his predecessor’s leadership.
